Predictors of relapses in patients with multiple sclerosis treated with disease-modifying drugs

被引：0
|
作者：
Steinman, L.
Obi-Tabot, E.
Wang, H.
Guilhaume, C.
Sondhi, M.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Sanofi Aventis R&D, Bridgewater, MA USA
[3] Sanofi Aventis R&D, Massy, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P921
引用
收藏
页码：S413 / S413
页数：1
相关论文
共 50 条
  • [1] Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis
    Kister, I.
    Spelman, T.
    Patti, F.
    Duquette, P.
    Trojano, M.
    Izquierdo, G.
    Lugaresi, A.
    Grammond, P.
    Sola, P.
    Ferraro, D.
    Grand'Maison, F.
    Alroughani, R.
    Terzi, M.
    Boz, C.
    Hupperts, R.
    Lechner-Scott, J.
    Kapos, L.
    Pucci, E.
    Hodgkinson, S.
    Solaro, C.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 356 - 357
  • [2] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [3] Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
    Otero-Romero, Susana
    Ascherio, Alberto
    Lebrun-Frenay, Christine
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 322 - 328
  • [4] Use of Disease-Modifying Drugs in Multiple Sclerosis
    Wurzius, F. Q.
    Silva, C. B.
    de Vecino, M. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 102 - 103
  • [5] Relationship between severe relapses and adherence to disease-modifying therapy in multiple sclerosis patients
    Meletiche, D.
    Kozma, C.
    Bennett, R.
    AL-Sabbagh, A.
    JOURNAL OF NEUROLOGY, 2008, 255 : 205 - 205
  • [6] Monitoring the use of disease-modifying drugs in multiple sclerosis
    Poluzzi, Elisabetta
    Piccinni, Carlo
    Sacripanti, Chiara
    Tola, Maria Rosaria
    D'Alessandro, Roberto
    Montanaro, Nicola
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S33 - S34
  • [7] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Trojano, Maria
    Paolicelli, Damiano
    Fuiani, Aurora
    Pellegrini, Fabio
    Iaffaldano, Pietro
    Direnzo, Vita
    D'Onghia, Mariangela
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
  • [8] The Disability Outcomes of Disease-Modifying Drugs in Multiple Sclerosis
    Hader, Walter
    NEUROLOGY, 2012, 78
  • [9] Multiple Sclerosis Disease-Modifying Drugs in Children and Adolescents
    Bykova O.V.
    Nankina I.A.
    Drozdova I.M.
    Kvasova O.V.
    Batysheva T.T.
    Boiko A.N.
    Neuroscience and Behavioral Physiology, 2017, 47 (5) : 544 - 552
  • [10] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Maria Trojano
    Damiano Paolicelli
    Aurora Fuiani
    Fabio Pellegrini
    Pietro Iaffaldano
    Vita Direnzo
    Mariangela D’Onghia
    Neurological Sciences, 2008, 29 : 225 - 226
12345